However, idelalisib treatment resulted in inhibition of AKT (pS473) (Fig. 3b, middle), and venetoclax treatment induced cleavage of caspase-3 (Fig. 3b, right), suggesting that these therapies were active in the patient’s CLL cells. The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.